HealthDay News—The extracutaneous manifestations of psoriasis and guidance on use of biologic treatment for management of psoriasis are discussed in 2 new guidelines published online Feb. 13 in the Journal of the American Academy of Dermatology.

Craig A. Elmets, MD, from the University of Alabama at Birmingham, and colleagues address the management of extracutaneous manifestations of psoriasis in adults, including comorbid conditions, mental health, psychological wellness, and quality of life. The authors emphasize the importance of communication between physicians and patients. Recognition of psoriasis as a chronic, multisystem inflammatory disorder is necessary to optimize management. Patient education, including discussion of etiology, potential comorbidities, treatment options, and lifestyle choices, will facilitate patient engagement and comprehensive care, as well as improve quality of life, according to the guideline.

Alan Menter, MD, from Baylor Scott & White Health in Dallas, and colleagues address the use of biologic agents in the treatment of psoriasis in adults. In general, US Food and Drug Administration-approved biologics are safe for psoriasis; however, dermatologists should be aware of common adverse events. Patients should be aware of the increased risk for infection and the importance of not discontinuing or modifying their treatment without dermatologist advice. Physicians should discuss efficacy and safety data with patients regarding initiation of a biologic or switching biologics. Before starting administration or switching biologic agents, quality-of-life assessments should be considered.

Related Articles

“Our goal in establishing these guidelines is to help health care professionals educate their patients on the best way to treat their disease and mitigate the effects psoriasis can have on a patient’s overall health and well-being,” Randy Beranek, president and CEO of the National Psoriasis Foundation, said in a statement.

Several authors from both guidelines disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text – Elmets

Abstract/Full Text – Menter